2. Inflammation/Immunology

Inflammation/Immunology (炎症/免疫)

Inflammation/Immunology

関連製品

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

製品番号 製品名 CAS 番号 純度 構造式
  • HY-157530
    VAP-1-IN-3 3054227-79-8 98%
    VAP-1-IN-3 (compound 136) is a potent amine oxidase vascular adhesion protein-1 (VAP-1) inhibitor, with an IC50 of 0.13 μM for VAP-1 isolated from bovine plasma. VAP-1-IN-3 can be used for the research of inflammatory.
    VAP-1-IN-3
  • HY-157578
    COX-2-IN-38 1018480-97-1 98%
    COX-2-IN-38 (compound 52*) is a potent inhibitor of COX-2, with the IC50 value of 79.4 nM.
    COX-2-IN-38
  • HY-15762R
    Valdecoxib (Standard) 181695-72-7 98%
    Valdecoxib (Standard) is the analytical standard of Valdecoxib. This product is intended for research and analytical applications. Valdecoxib is a highly potent and selective inhibitor of COX-2, with IC50s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain.
    Valdecoxib (Standard)
  • HY-157725
    C18:1 LPA 799279-68-8 98%
    C18:1 LPA, a bioactive lipid derived from membrane phospholipids, plays a crucial role in various cellular processes and is found in blood plasma, where it is linked to neurological disorders, inflammation, and cancer.
    C18:1 LPA
  • HY-15790R
    Elobixibat (Standard) 439087-18-0 98%
    Elobixibat (Standard) is the analytical standard of Elobixibat (HY-15790). This product is intended for research and analytical applications. Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly.
    Elobixibat (Standard)
  • HY-15790S
    Elobixibat-d5 98%
    Elobixibat-d5 is the deuterium labeled Elobixibat (HY-15790). Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly.
    Elobixibat-d5
  • HY-15851R
    Revefenacin (Standard) 864750-70-9
    Revefenacin (Standard) is the analytical standard of Revefenacin. This product is intended for research and analytical applications. Revefenacin (TD-4208; GSK1160724) is a potent mAChR antagonist; has a high affinity on M3 receptor with a Ki of 0.18 nM.
    Revefenacin (Standard)
  • HY-15853A
    MK-7246 S enantiomer 2310135-53-4 98%
    MK-7246 S enantiomer is the less active enantiomer of MK-7246. MK-7246 is a potent and selective CRTH2 antagonist.
    MK-7246 S enantiomer
  • HY-158623
    (±)13(14)-DiHDPA 1345275-24-2 98%
    (±)13(14)-DiHDPA ((±)13,14-DiHDPE) a metabolite of Docosahexaenoic acid (DHA; HY-B2167) by P450 (CYP) metabolic pathways.
    (±)13(14)-DiHDPA
  • HY-159161
    PSB-CB-27 2237222-16-9 98%
    PSB-CB-27 is a potent and selective GPR18 inhibitor with an IC50 of 0.65 μM. PSB-CB-27 shows selectivity over Human GPR55, Human CB1 receptor, and Human CB2 receptor. PSB-CB-27 leads to a complete blockade of Δ9-Tetrahydrocannabinol (THC)-induced GPR18 activation. PSB-CB-27 can be used for inflammatory diseases and cancer immunotherapy research.
    PSB-CB-27
  • HY-159477
    SARS-CoV-2-IN-92 2123489-12-1 98%
    SARS-CoV-2-IN-92 (compound 11) inhibits SARS-CoV-2 variants (EC50 = 0.48 μM), as well as SARS-CoV and MERS-CoV. SARS-CoV-2-IN-92 (compound 11) potently and selectively blocks ERα-Glu II.
    SARS-CoV-2-IN-92
  • HY-15950R
    AZD1981 (Standard) 802904-66-1 98%
    AZD1981 (Standard) is the analytical standard of AZD1981. This product is intended for research and analytical applications. AZD1981 is the antagonist for GPR44 (also known also PTGDR2, DP2 or CRTh). AZD1981 blocks the binding of PGD2 to CRTH2. AZD1981 exhibits immunomodulatory effects and can be used in research of chronic spontaneous urticaria.
    AZD1981 (Standard)
  • HY-159671
    3D-Monophosphoryl Lipid (14) 252042-59-4 98%
    3D-Monophosphoryl Lipid (14) (3D-Monophosphoryl Lipid (14)) is a TLR4 agonist that can be used as a vaccine adjuvant to enhance the immunogenicity of vaccines.
    3D-Monophosphoryl Lipid (14)
  • HY-159686
    Aclidinium 727649-81-2 98%
    Aclidinium is a long-acting muscarinic antagonist and long-acting β2-adrenoceptor (β2-AR) agonist with bronchodilator activity. Aclidinium can reduce hyperinflation of the lungs and increase lung function and exercise endurance time. Aclidinium is used in research on chronic obstructive pulmonary disease (COPD).
    Aclidinium
  • HY-159905
    HPK1-IN-54 3048537-48-7 98%
    HPK1-IN-54 is a potent HPK1 (Hematopoietic Progenitor Kinase 1) inhibitor that enhances T cell activation and proliferation by inhibiting HPK1 activity, thereby exhibiting antitumor effects. Its IC50 value against HPK1 is 2.67 nM, with excellent selectivity over the MAP4K family (>100-fold) and other selected kinases (>300-fold). HPK1-IN-54 displayed moderate in vivo clearance and reasonable oral exposure in mice and rats. Additionally, HPK1-IN-54 demonstrated strong antitumor efficacy in a CT26 murine colon cancer model and synergistic effects when combined with anti-PD-1 (HY-P9902A). HPK1-IN-54 shows promise for research in the field of immunotherapy.
    HPK1-IN-54
  • HY-159919
    UM-3006 1927013-87-3 98%
    UM-3006 is a highly efficient TLR7/8 agonist that enhances immune responses by activating the TLR signaling pathway. UM-3006 holds significant research and application potential in the fields of vaccine adjuvants and immune diseases.
    UM-3006
  • HY-160121
    Patrinoside aglucone 76319-15-8 98%
    Patrinoside aglucone (Compound 8) is an iridoid glucoside that can be isolated from the Valeriana tuberosa. Patrinoside aglucone has potent anticancer activity with G2/M phase tumor cell cycle arrest and apoptosis induction. Patrinoside aglucone also significantly inhibits the proliferation of cancer stem cells (such as MDA-MB-231 and U-251MG cells). Patrinoside aglucone has great anti-inflammatory activity by inhibiting NO release (IC50: 43.44 μM) and significantly reduces the level of TNF-α, IL-1β, IL-6, PGE2 and COX-2.
    Patrinoside aglucone
  • HY-160265
    URAT1 inhibitor 9 2251727-90-7 98%
    URAT1 inhibitor 9 (Compound 24) is an URAT1 inhibitor that can be used in the study of gout or hyperuricemia.
    URAT1 inhibitor 9
  • HY-160420
    Cinoxolone 31581-02-9 98%
    Cinoxolone, a derivative of glycyrrhetinic acid, is an antiulcer agent.
    Cinoxolone
  • HY-160446
    BET-IN-24 2407658-21-1 98%
    Bet-in-24 (example 2) is a bromodomain and extra-terminal (BET) inhibitor. BET-IN-24 can be used in the study of virology, heart failure, inflammation, central nervous system (CNS) diseases and many cancers
    BET-IN-24
製品番号 製品名 / Synonyms Application Reactivity